Drug
Tak 063
Tak 063: highest development phase Phase 2, developed by Takeda. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Takeda
Trials
| Drug | Phase | Indication |
|---|---|---|
| TAK-063 20 mg NCT02477020 | Phase 2 | Schizophrenia |
Latest
No recent events.
Follow Tak 063 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.